Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities: 2017

Historic Preferred Stock Liabilities for Crinetics Pharmaceuticals (CRNX) over the last 1 years, with Dec 2017 value amounting to $29.7 million.

  • Crinetics Pharmaceuticals' Preferred Stock Liabilities was N/A to $93.0 million in Q2 2018 from the same period last year, while for Jun 2018 it was $93.0 million, marking a year-over-year change of. This contributed to the annual value of $29.7 million for FY2017, which is N/A change from last year.
  • As of FY2017, Crinetics Pharmaceuticals' Preferred Stock Liabilities stood at $29.7 million.
  • In the past 5 years, Crinetics Pharmaceuticals' Preferred Stock Liabilities ranged from a high of $29.7 million in FY2017 and a low of $29.7 million during FY2017.
  • Its 1-year average for Preferred Stock Liabilities is $29.7 million, with a median of $29.7 million in 2017.